Skip to main content

Table 1 Baseline characteristics of the patientsa

From: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

  RA (n= 17) SpA (n= 91)
Characteristics ATIpos (n= 7) ATIneg (n= 10) Pvalue ATIpos (n= 14) ATIneg (n= 77) Pvalue
Age, years 49 (28 to 65) 47 (36 to 64) 0.7 47 (36 to 73) 44 (14 to 76) 0.2
Body mass index, kg/m2 25.9 (20.2 to 34.8) 23.5 (16.4 to 34.6) 0.5 24.8 (17.5 to 32.8) 26.1 (15.8 to 45.8) 0.1
Disease duration, years 6.0 (1 to 12) 10 (2 to 30) 0.07 8.9 (0 to 24) 5 (0 to 24) 0.3
Infliximab dose, mg/kg 3.0 (2.8 to 3.7) 3.6 (2.6 to 5.4) 0.09 4.9 (2.9 to 5.7) 5.0 (2.8 to 6.7) 0.4
Concomitant treatments
   MTX, n (%) 3 (43) 6 (60) 0.8 0 (0) 25 (32) 0.03
   Prednisone, n (%) 4 (57) 8 (80) 0.6 2 (14) 12 (16) 0.8
ESR, mm/hour 14 (7 to 58) 24 (2 to 114) 0.5 8 (2 to 54) 10 (1 to 89) 0.6
CRP, mg/L 10 (3 to 81) 16 (3 to 124) 0.9 3 (1 to 72) 5 (1 to 74) 0.9
  1. aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA: spondyloarthritis; MTX: methotrexate; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein. Results are given as medians (ranges) unless otherwise indicated.